Ascensia Diabetes Care Archives - Medical Design Sourcing

Ascensia expands payment program for Senseonics Eversense E3 CGM

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced today that it expanded the Eversense PASS program for the Senseonics (NYSE:SENS) Eversense E3 CGM.

Eversense PASS, a payment assistance and simple savings program, aims to enhance affordability and access to Eversense E3. Ascensia serves as the global commercial partner for Senseonics. The Senseonics continuous glucose monitor (CGM), a 180-day implantable CGM, received FDA approval in February of last year.

It features a third-generation sensor with SBA technology that enhances sensor longevity. This makes it — according to Senseonics — the longest-lasting CGM system. The fully implantable sensor requires just two insertion and removal procedures per year.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia partners with Snaq on diabetes management

The Contour Next One blood glucose meter. [Image from Ascensia Diabetes Care]Ascensia Diabetes Care announced today that it entered into a global collaboration with diabetes management company Snaq.

Snaq develops an app-based solution offering insights on food and nutrition for people with diabetes. Ascensia develops the Controu blood glucose monitoring system and distributes Senseonics’ Eversense CGM systems. The companies plan to integrate technologies to help with mealtime decisions and improve diabetes management.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia Diabetes integrates its Eversense CGM with Apple Health

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced today that it has updated its Eversense Continuous Glucose Monitoring system app to integrate with Apple Health.

The Parsippany, N.J.-based company makes the Contour Blood Glucose Monitoring (BGM) system and distributes Senseonics’ Eversense CGM system. The new Apple Health integration will allow people with diabetes using Senseonics’ Eversense CGM systems to view glucose data within the Apple Health app. In addition, they can also see other health metrics on the iPhone’s health and wellbeing platform.

Eversense CGM is a fully-implantable CGM with a sensor that has a 6-month sensor wear duration. The system transmits data to the Eversense CGM app. There, users can view, analyze and share glucose data. In addition, it alerts users to changes and trends in glucose levels as well.

The new integration allows users in all markets where Eversense is availab…

Ascensia, Senseonics partner with Nurse Practitioner Group on CGM insertion options

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) and Ascensia Diabetes Care launched a collaboration with the Nurse Practitioner Group (NPG) today.

NPG offers multidisciplinary health services and medical staffing solutions. The collaboration aims to broaden access to the Eversense E3 continuous glucose monitor (CGM) system. Senseonics developed Eversense E3 and Ascensia distributes the system as the company’s partner.

The collaboration offers convenient at-home and in-office insertion options for diabetes patients. NPG recently completed the first patient insertion of the six-month Eversense E3 sensor in Florida. It plans to expand the initiative to other key markets across the U.S. in the coming months.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia launches online diabetes management, analytics platform in U.S.

[Image from Ascensia Diabetes Care]Ascensia Diabetes Care announced today that it launched its online diabetes management and analytics platform in the U.S.

Parsippany, New Jersey-based Ascensia now offers GlucoContro.online in more than 15 countries around the world. It plans for further expansion, too.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia completes Senseonics Eversense E3 European launch

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced that it successfully completed its initial European launch for the Senseonics (NYSE:SENS) Eversense E3.

Eversense E3 represents Senseonics’ next-generation continuous glucose monitor (CGM) system. Eversense E3 can be used for up to six months (180 days). This doubles the wear time of its previous-generation CGM.

Ascensia said in a news release that its launch extends to Germany, Switzerland, Poland, Italy, Spain, Norway, Sweden, the Netherlands, and Andorra. The company began its phased rollout for Eversense E3 in August.

The system received CE mark approval in June.

Get the full story at our sister site, Drug Delivery Business News.

Senseonics wins CE mark approval for 180-day Eversense E3 CGM

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system.

Germantown, Maryland-based Senseonics offered its previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days).

Get the full story at our sister site, Drug Delivery Business News.

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.

From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.

Here are five of the biggest stories to come out of ATTD 2022:

Dexcom’s G7 is accurate in pediatric T1D patients

Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

Get the full story at our sister site, Drug Delivery Business News.

Study shows fewer out-of-target blood glucose levels using Ascensia’s monitoring system

Ascensia Diabetes Care announced today that a new study demonstrates reduced out-of-target blood glucose ranges with its Contour system.

The company, which distributes Senseonics’ Eversense continuous glucose monitor (CGM), develops the Contour blood glucose monitoring (BGM) systems and the Contour diabetes app (CDA) for people with diabetes who are managing their blood glucose levels.

Get the full story at our sister site, Drug Delivery Business News.

Senseonics announces first Eversense E3 CGM implant in U.S.

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor.

Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia launches Senseonics’ next-gen 180-day Eversense E3 CGM in U.S.

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced today that it launched the Senseonics (NYSE:SENS) Eversense E3 system in the U.S.

The next-generation Eversense E3 continuous glucose monitoring (CGM) system, developed by Germantown, Maryland-based Senseonics, received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S.

Get the full story at our sister site, Drug Delivery Business News.

9am.health partners with Ascensia to add blood glucose meter to diabetes toolkit

9am.health announced today that it now offers the Ascensia Diabetes Care Contour Next One and Contour Next products in its diabetes kit.

San Diego-based 9am.health patients with type 2 diabetes and prediabetes can now add Ascensia’s Contour Next One blood glucose meter and Contour Next glucose test strips to a personalized treatment plan as part of 9am.health’s all-in-one virtual diabetes care offering.

Get the full story at our sister site, Drug Delivery Business News.